Cardiovascular protective effects of resveratrol

Cardiovascular Drug Reviews

Volumn 22, Issue 3, 2004, Pages 169-188

  Bradamante, Silvia ^a   Barenghi, Livia ^a   Villa, Alessandro ^a  

^a CNR   (Italy)

Author keywords

Adenosine; Antioxidants; Cardiovascular protection; LDL oxidation; Nitric oxide; Platelet aggregation; Preconditioning; Resveratrol

Indexed keywords

8 (4 SULFOPHENYL)THEOPHYLLINE; ADENOSINE; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BUTYLCRESOL; GALLIC ACID PROPYL ESTER; HYDROXYL RADICAL; LOW DENSITY LIPOPROTEIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; POLYPHENOL; PROCOAGULANT; RESVERATROL; THROMBOPLASTIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; BIOAVAILABILITY; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; ISOLATED HEART; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 6344278438     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2004.tb00139.x     Document Type: Review

References (105)

1. Adams MR, Kinlay S, Blake GJ, Orford JL, Ganz P, Selwyn AP. Atherogenic lipids and endothelial dysfunction: Mechanisms in the genesis of ischemic syndromes. Annu Rev Med 2000;51:149-167.
2. Andlauer W, Kolb J, Siebert K, Fürst P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res 2000;26:47-55.
3. Andrus MB, Liu J, Meredith EL, Nartey E. Synthesis of resveratrol using a direct decarbonylative Heck approach from resorcylic acid. Tetrahedron Lett 2003;44:4819-4822.
4. Aumont V, Krisa S, Battaglia E, et al. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch Biochem Biophys 2001;393:281-289.
5. Becker JVW, Armstrong GO, van der Merwe MJ, Lambrechts MG, Vivier MA, Pretorius IS. Metabolic engineering of Saccharomyces cerevisiae for the synthesis of the wine-related antioxidant resveratrol. FEMS Yeast Res 2003;4:19-85.
6. Belguendouz L, Frémont L, Gozzelino MT. Interaction of trans-resveratrol with plasma lipoproteins. Biochem Pharmacol 1998;55:811-816.
7. Bertelli AAE, Giovannini L, Stradi R, Uriens S, Tillement JP, Bertelli A. Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res 1998;24:51-55.
8. Blache D, Rustan I, Durand P, Lesgards G, Loreau N. Gas Chromatographic analysis of resveratrol in plasma, lipoproteins and cells after in vitro incubations. J Chromatogr 1997;702:103-110.
9. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: An overview of a decade of research. J Mol Cell Cardiol 2001;33: 1897-1918.
10. Bradamante S, Piccinini F, Barenghi L, et al. Does resveratrol induce pharmacological preconditioning? Int J Tissue React 2000;22:1-4.
11. Bradamante S, Barenghi L, Piccinini F, et al. Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. Eur J Pharmacol 2003;465:115-123.
12. Brito P, Almeida LM, Dinis TCP. The interaction of resveratrol with ferrylmyoglobin and peroxynitrite; protection against LDL oxidation. Free Radio Res 2002;36:621-631.
13. Cannon RO. Role of nitric oxide in cardiovascular disease: Focus on the endothelium. Clin Chem 1998;44: 1809-1919.
14. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 1996;27:363-366.
15. Constant J. Alcohol, ischemic heart disease, and the French paradox. Comn Artery Dis 1997;8:645-649.
16. Cook NC, Samman S. Flavonoids-chemistry, metabolism, Cardioprotective effects, and dietary sources. J Nutr Biochem 1996;7:66-76.
17. Davies MJ. The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res 1996;82:1-32.
18. de Lorgeril M, Salen P, Paillard F, Laporte F, Boucher F, de Leiris J. Mediterranean diet and the French paradox: Two distinct biogeographic concepts for one consolidated scientific theory on the role of nutrition in coronary heart disease. Cardiovasc Res 2002;54:503-515.
19. Diebolt M, Bucher B, Andriantsitohaina R. Wine polyphenols decrease blood pressure, improve NO vasodilatation, and induce gene expression. Hypertension 2001;38:159-165.
20. Dobrydneva Y, Williams RL, Morris GZ, Blackmore PF. Dietary phytoestrogens and their synthetic structural analogues as calcium channel blockers in human platelets. J Cardiovasc Pharmacol 2002;40:399-410.
21. Draczynska-Lusiak B, Chen YM, Sun AY. Oxidized lipoproteins activate NF-kappaB binding activity and apoptosis in PC12 cells. Neuroreport 1998;9:527-532.
22. Duthie GG, Pedersen MW, Gardner PT, et al. The effect of whisky and wine consumption on total phenol content and antioxidant capacity of plasma from healthy volunteers. Eur J Clin Nutr 1998;52:733-736.
23. El-Mowafy AM, White RE. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: Reversal of endothelin-1 stimulatory effects. FEBS Lett 1999;451:63-67.
24. Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, Merillon J-M. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis Vinifera cell cultures using in vitro tests. Life Sci 1997;61:2103-2110.
25. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet 1993; 341:1103-1104.
26. Fremont L. Biological effects of resveratrol. Life Sci 2000;66:663-673.
27. Galati G, Sabzevari O, Wilson JX, O'Brien PJ. Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 2002;177:91-104.
28. Gamoh K, Nakashima K. Liquid chromatography/mass spectrometric determination of trans-resveratrol in wine using a tandem solid-phase extraction method. Rapid Commun Mass Spectrom 1999;13:1112-1115.
29. Gescher AJ, Steward WP. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiol Biomarkers Prev 2003;12:953-957.
30. Goldberg DM, Yan J, Ng E, et al. Direct injection gas chromatographic mass spectrometric assay for trans-resveratrol. Anal Chem 1994;66:3959-3963.
31. Goldberg DM, Hahn SE, Parkes JG. Beyond alcohol: Beverage consumption and cardiovascular mortality. Clin Chim Acta 1995;237:155-187.
32. Goldberg DM, Garovic-Kocic V, Diamandis EP, Pace-Asciak CR. Wine: Does the colour count? Clin Chim Acta 1996;246:183-193.
33. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003;36:79-87.
34. Goldberg DM, Soleas GH. Resveratrol: Biochemistry, cell biology and the potential role in disease prevention. In: Sandier M and Pinder R ed. Wine: a scientific exploration. London and New York: Taylor & Francis, 2003;161-198.
35. Gu X, Chu Q, O'Dwyer M, Zeece M. Analysis of resveratrol in wine by capillary electrophoresis. J Chromatogr A 2000;881:471-481.
36. Guo Y, Jones WK, Xuan YT, et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA 1999;96:11507-11512.
37. Haider UGB, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM. Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells. Mol Pharmacol 2002;62:772-777.
38. Hall SS. Longevity research: In Vino vitalis? Compounds activate life-extending genes. Science 2003;301: 1165.
39. Hattori R, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: Role of nitric oxide. Am J Physiol 2002;282:H1988-H1995.
40. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-196.
41. Hsieh T-C, Juan G, Darzynkiewicz Z, Wu JM. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21WAF1/CIP1, and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res 1999;59:2596-2601.
42. Hung L-M, Chen J-K, Huang S-S, Lee R-S, Su M-J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 2000;47:549-555.
43. Ignatowicz E, Baer-Dubowska W. Resveratrol, a natural chemopreventive agent against degenerative diseases. Pol J Pharmacol 2001;53:557-569.
44. Imamura G, Bertelli AA, Bertelli A, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: An insight with iNOS knockout mice. Am J Physiol 2002;282:H1996-H2003.
45. Jager U, Nguyen-Duong H. Relaxant effect of trans resveratrol on isolated porcine coronary arteries. Arzneimittelforschung 1999;49:207-211.
46. Juan ME, Buenafuente J, Casals I, Planas JM. Plasmatic levels of trans-resveratrol in rats. Food Res Int 2002;35:195-199.
47. Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002;132:257-260.
48. Kirk RI, Deitch JA, Wu JM, Lerea KM. Resveratrol decreases early signaling events in washed platelets but has little effect on platelets in whole food. Blood Cells Mol Dis 2000;26:144-150.
49. Kovanen PT, Pentikäinen MO. Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis. Curr Opin Lipidol 2003;14:411-419.
50. Kris-Etherton PM, Hecker KD, Bonanome A, et al. Bioactive compounds in foods: Their role in the prevention of cardiovascular disease and cancer. Am J Med 2002;113:71S-88S.
51. Kuhnle G, Spencer JP, Chowrimootoo G, et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 2000;272:212-217.
52. Laden BP, Porter TD. Resveratrol inhibits human squalene monooxygenase. Nutr Res (New York) 2001;21: 747-753.
53. Latruffe N, Delmas D, Jannin B, Cherkaoui Malki M, Passilly-Degrace P, Berlot J-P. Molecular analysis on the chemopreventive properties of resveratrol, a plant polyphenol microcomponent. Int J Mol Med 2002;10: 755-760.
54. Leikert JF, Räthel TR, Wohlfart P, Cheynier V, Vollmar AM, Dirsch VM. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation 2002;106:1614-1617.
55. Leonard SS, Xia C, Jiang BH, et al. Resveratrol scavenges reactive oxygen species and affects radical-induced cellular responses. Biochem Biophys Res Commun 2003;309:1017-1026.
56. + current in vascular endothelial cells. Cardiovasc Res 2000;45:1035-1045.
57. Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 2003;64:1029-1036.
58. Maccarrone M, Lorenzon T, Guerrieri P, Agro AF. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem 1999;265:27-34.
59. Marier J-F, Vachon P, Gritsas A, Zhang J, Moreau J-P, Ducharme MP. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Ther 2002;302:369-373.
60. Martin S, Andriantsitohaina R. Cellular mechanism of vasculo-protection induced by polyphenols on the endothelium. Ann Cardiol Angeiol (Paris) 2002;51:304-315.
61. Martinet W, Kockx MM. Apoptosis in atherosclerosis: Focus on oxidized lipids and inflammation. Curr Opin Lipidol 2001;12:535-541.
62. Martinez J, Moreno JJ. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 2000;59:865-870.
63. McMurtrey KD, Minn J, Pobanz K, Schultz TP. Analysis of wines for resveratrol using direct injection high-pressure liquid chromatography with electrochemical detection. J Agric Food Chem 1994;42: 2077-2080.
64. Miura T, Muraoka S, Ikeda N, Watanabe M, Fujimoto Y Antioxidative and prooxidative action of stilbene derivatives. Pharmacol Toxicol 2000;86:203-208
65. Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci 2003;73:1393-1400.
66. Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 2000;274:61-67.
67. Mnjoyan ZH, Fujise K. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: A role of p53-p21(WAF1/CIP1) pathway. Biochem Biophys Res Commun 2003;311:546-552.
68. Moridani MY, Galati G, O'Brien PJ. Comparative quantitative structure toxicity relationships for flavonoids evaluated in isolated rat hepatocytes and HeLa tumor cells. Chem Biol Interact 2002;139:251-264.
69. Naderali EK, Doyle PJ, Williams G. Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs. Clin Sci (Colch) 2000;98:537-543.
70. Nihei T, Miura Y, Yagasaki K. Inhibitory effect of resveratrol on proteinuria, hypoalbuminemia and hyperlipidemia in nephritic rats. Life Sci 2001;68:2845-2852.
71. Orallo F, Alvarez E, Camina M, Leiro JM, Gomez E, Fernandez P. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol 2002;61: 294-302.
72. Orsini F, Pelizzoni F, Verotta L, Aburjai T, Rogers CB. Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds. J Nat Prod 1997;60:1082-1087.
73. Pal S, Ho N, Santos C, Dubois P, et al. Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutr 2003;133:700-706.
74. Pendurthi UR, Williams JT, Rao LVM. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells. A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler Thromb Vasc Biol 1999;19:419-426.
75. Pendurthi UR, Rao LVM. Resveratrol suppresses agonist-induced monocyte adhesion to cultured human endothelial cells. Thromb Res 2002;106:243-248.
76. Pervaiz S. Resveratrol: From grapevines to mammalian biology. FASEB J 2003;17:1975-1985.
77. Pezet R, Pont V, Cuenat P. Method to determine resveratrol and pterostilbene in grape berries and wines using high-performance liquid chromatography and highly sensitive fluorimetric detection. J Chromatogr A 1994;663:191-197.
78. 2: in human low-density lipoprotein. Biochim Biophys Acta 2002;1583:176-184.
79. Ray PS, Maulik G, Cordis GA, Bertelli AAE, Bertelli A, Das DK. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 1999;27:160-169.
80. Ruef J, Moser M, Kubler W, Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol 2001;10:311-315.
81. Sanchez-Moreno C, Jimenez-Escrig A, Saura-Calixto F. Study of low-density lipoprotein oxidizability indexes to measure the antioxidant activity of dietary polyphenols. Nutr Res (New York) 2000;20:941-953.
82. Sato M, Suzuki Y, Okuda T, Yokotsuka K. Contents of resveratrol, piceid, and their isomers in commercially available wines made from grapes cultivated in Japan. Biosci Biotechnol Biochem 1997;61:1800-1805.
83. Seimann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 1992; 43:49-52.
84. Sharp D. Château resveratrol. Lancet 2003;361:1404.
85. Shigematsu S, Ishida S, Hara M, et al. Resveratrol, a red wine constituent polyphenol, prevents super-oxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 2003;34:810-817.
86. Scares DG, Andreazza AC, Salvador M. Sequestering Ability of Butylated Hydroxytoluene, Propyl Gallate, Resveratrol, and Vitamins C and E against ABTS. DPPH, and Hydroxyl Free Radicals in Chemical and Biological Systems. J Agric Food Chem 2003;51:1077-1080.
87. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: A molecule whose time has come? And gone? Clin Biochem 1997;30:91-113.
88. Soleas GJ, Yan J, Goldberg DM. Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Biomed Appl 2001;757:161-172.
89. Soleas GJ, Angelini M, Grass L, Diamandis EP, Goldberg DM. Absorption of trans-resveratrol in rats. Methods Enzymol 2001;335:145-154.
90. Takano H, Bolli R, Black RG et al. A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ Res 2001;88:520-528.
91. Taubert D, Berkels R. Upregulation and activation of eNOS by resveratrol. Circulation 2003;107:E78.
92. Turrens JF, Lariccia J, Gopal Nair M. Resveratrol has no effect on lipoprotein profile and does not prevent peroxidation of serum lipids in normal rats. Free Radic Res 1997;27:557-562.
93. 14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 2003;72:2219-2233.
94. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002;106:1652-1658.
95. Wang M, Jin Y, Ho C-T. Evaluation of resveratrol derivatives as potential antioxidants and identification of a reaction product of resveratrol and 2,2-diphenyl-1-picryhydrazyl radical. J Agric Food Chem 1999;47: 3974-3977.
96. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 2002;50:431-435.
97. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: New discoveries and rapid progress in the clinic. Trends Pharmacol Sci 1998;19:5-8.
98. Wilson T, Knight TJ, Beitz DC, Lewis DS, Engen RL. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 1996;59:15-21.
99. Wolter F, Stein J. Biological activities of resveratrol and its analogs. Drugs Future 2002;27:949-959.
100. Yang LC, Wang F, Liu M. A study of an endothelin antagonist from a Chinese anti-snake venom medicinal herb. J Cardiovasc Pharmacol 1998;31:S249-S250.
101. Yla-Herttuala S. Oxidized LDL and atherogenesis. Ann NY Acad Sci 1999;874:134-137.
102. Zhao T, Xi L, Chelliah J, Levasseur JE, Kukreja RC. Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A(1) receptors: Evidence from gene-knockout mice. Circulation 2000;102:902-907.
103. Zhu Z, Klironomos G, Vachereau A, Neirinck L, Goodman DW. Determination of trans-resveratrol in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999;724: 389-392.
104. Zou J, Huang Y, Cao K, et al. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci 2000;68:153-163.
105. Zou J-G, Wang Z-R, Huang Y-Z, Cao K-J, Wu JM. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int J Mol Med 2003;11:317-320.